ArticleBMC cancer2019
Salvage PRRT with
Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04954820 (A Prospective Randomized Phase II Study Assess the Schema of Retreatment With Lutathera®), which is not on this map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Randomized Phase II Study Assess the Schema of Retreatment With Lutathera® ([177LU]LU-DOTA-TATE) in Patients With New Progression of Intestinal Well-differenciated Neuroendocrine Tumor
Who cites it
44 citing papers in PubMed, 81 citations in OpenAlex.
- Trial
- Krenning score enhances integrated biomarker models for survival prediction in PRRT-treated GEP-NET: a retrospective cohort study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Patient selection for PRRT rechallenge in neuroendocrine tumors: impact of initial response duration on outcomes.European journal of nuclear medicine and molecular imaging · 2026Article
- Comparative assessment of KDIGO and CTCAE criteria for detecting renal function deterioration after peptide receptor radionuclide therapy.European journal of nuclear medicine and molecular imaging · 2026Article
- Article
- Estimation of split renal function on PET using the SSTR-targeting radioligands [European journal of nuclear medicine and molecular imaging · 2026Article
- Dosimetry inJournal of clinical medicine · 2026Review
- PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).Endocrine-related cancer · 2026Review
- Anatomical-biochemical discordance and prognostic role of bone metastases in advanced MTC treated with [¹⁷⁷Lu]Lu-DOTA-TATE.BMC cancer · 2025Article
- Safety and efficacy of re-treatment with [European journal of nuclear medicine and molecular imaging · 2025Article
- Repeat Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors: A NET Center of Excellence Experience.Journal of gastrointestinal cancer · 2024Article
- Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update.Current oncology reports · 2024Review
- Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles.European journal of nuclear medicine and molecular imaging · 2024Article
- Article
- LutatheraPharmaceutics · 2023Review
- Review
- Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade.Frontiers in endocrinology · 2023Review
- Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms.Nutrients · 2022Article
- The efficacy, toxicity and survival of salvage retreatment PRRT withThe British journal of radiology · 2022Article
- Update to "Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors".The oncologist · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
backgroundNETTER-1 trial demonstrated high efficacy and low toxicity of four cycles of Peptide Receptor Radionuclide Therapy (PRRT) in patients with metastasized NET. The present study evaluates the outcome of further PRRT cycles in the so called salvage setting in patients after initial response to four therapy cycles and later progression.
methodsThirty five patients (pat.) (25 male, 10 female, 63 ± 9 years) with progressive, metastasized NET (23 small intestinal, 5 lung, 4 CUP, 1 rectal, 1 gastric and 1 paraganglioma) were included. All patients previously received 4 PRRT cycles with
resultsThe median PFS after initial PRRT was 33 months (95% CI: 30-36). The mean cumulative dose for including salvage PRRT was 44 GBq (range 33.5-47). One pat. (2.9%) showed grade 3 hematotoxicity. Kidney dosimetry revealed a mean cumulative kidney dose after a median of 6 PRRT cycles of 23.8 Gy. No grade 3 / 4 nephrotoxicity or relevant decrease in renal function was observed. Follow-up imaging was available in 32 patients after salvage therapy. Best response according to RECIST 1.1. was PR in one patient (3.1%), SD in 26 patients (81.3%) and PD in 5 patients (15.6%). PFS after salvage therapy was 6 months (95% CI: 0-16; 8 patients censored). Mean OS after initial PRRT was 105 months (95% CI: 92-119) and 51 months (95% CI: 41-61) after start of salvage therapy. Median OS was not reached within a follow-up of 71 months after initial PRRT and 25 months after start of salvage PRRT, respectively.
conclusionsSalvage therapy with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.